Testing fianlimab with cemiplimab before surgery for melanoma
Tests fianlimab and cemiplimab before surgery in people with melanoma skin cancer.
Key facts
- Who runs it
- University of California, Irvine
- Where
- Orange, United StatesSee the site
- Trial code
- Registry title
- Fianlimab&Cemiplimab as TotalNeoadj The (TNT) ForMelanoma
- Status
- Not yet recruiting
- Phase
- Phase 2
- People taking part
- 35 people, planned
- Starts
- Dec 2026
- Expected to end
- 1 Feb 2030
- Type of study
- Interventional, 3 groups
- Treatments tested
- Fianlimab
- Cemiplimab
- Record updated
- 11 September 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with melanoma of the skin that can be removed by surgery (stage IIIB-D, or stage IV with few spread sites). They get fianlimab with cemiplimab before surgery.
- Age
- 18 years or older
- Sex
- All sexes can join.
- Disease stage
- Melanoma of the skin that surgery can remove: stage IIIB-D, or stage IV (M1a, M1b, M1c) with few spread sites. At the first diagnosis or after a return following earlier surgery. More than 1 measurable lesion by RECIST.
- Earlier treatment
- No earlier immunotherapy for melanoma or another cancer.
Main reasons for not taking part
- Spread to organs, bone or brain
- Acral, eye or mucosal melanoma
- Earlier immunotherapy for melanoma or another cancer
- History of myocarditis, or an autoimmune disease treated with immune-suppressing drugs in the last 2 years
- Past solid organ or tissue transplant from another person; pregnant or breastfeeding women
The registry criteria, word for word
Show all 37 criteriaShow less
Who can take part
- ≥18 years at the time of signing informed consent form (ICF) and able to independently complete informed consent. A certified translator must be used in the completion of informed consent for non-English speaking individuals
- Patients must have surgically resectable, macroscopic Stage IIIB-D cutaneous melanoma or oligometastatic resectable stage IV (M1a, M1b, and M1c) melanoma per American Joint Committee on Cancer 8th Edition Staging Criteria. Patients are eligible at the time of the initial diagnosis or recurrence after previous surgery. Patients should have > 1 RECIST measurable lesion
- Participants must have Eastern Cooperative Group (ECOG) performance status score of 0, 1 or 2 at initial screening
- Life expectancy of at least 12 weeks
- Adequate bone marrow, liver, and renal function:
- Hemoglobin >8.0 g/dL
- Platelets >75/mm3
- ANC >1.5/mm3
- Creatinine Clearance > 30mL/min
- AST and ALT less than 3 times the Upper Limit of Normal. participants with Gilbert's syndrome are excluded if total bilirubin > 3.0 × ULN; or direct bilirubin > 1.5 × ULN
- Total Bilirubin < 3.1
- Albumin ≥ 3.0 g/dL
- Absolute neutrophil count ≥ 1.5 × 109/L
- Absolute lymphocyte count ≥ 0.5 × 109/L
- Women of childbearing potential must have had a negative pregnancy test performed within 7 days prior to the start of treatment
- Females of childbearing potential and males must be willing and able to use a highly effective method of contraception to avoid pregnancy for the duration of the study and for at least 6 months after the last dose of study treatment. Acceptable means of contraception are listed in the fianlimab institutional brochure
- Male participants must be willing to abstain from donating sperm from the time of enrollment until 6 months after administration of study interventions
Who cannot take part
- Participants with previous treatment with investigational or standard immunotherapy for melanoma or other malignancy
- Known HBV infection defined as hepatitis B surface antigen reactive. NOTE: Participants with HBV infection on stable anti-viral therapy for > 4 weeks prior to the planned first study intervention and viral load confirmed as undetectable during Screening may be eligible
- Known active HCV infection defined as detectable HCV RNA (qualitative) infection. NOTE: History of HCV is not exclusionary if participant has received curative treatment and viral load is confirmed as undetectable during Screening
- History or current evidence of significant (CTCAE grade ≥2) local or systemic infection (eg, cellulitis, pneumonia, septicemia) requiring systemic antibiotic treatment within 2 weeks prior to the first dose of trial medication
- Ongoing or recent (within 2 years) evidence of an autoimmune disease that required systemic treatment with immunosuppressive agents except for the following: . The following are non-exclusionary: vitiligo, childhood asthma that has resolved, residual hypothyroidism that requires only hormone replacement, psoriasis not requiring systemic treatment
- Live vaccine within 30 days of the planned administration of a study drug
- Participants with a local recurrence in scar or surgical bed of the primary melanoma as the sole site of disease
- Participants with N1a or N2a only disease
- Participants with a history of a malignant disease that can interfere with interpretation of study results
- Patients with a history of myocarditis
- Known hypersensitivity to the active substances or to any of the excipients
- Participants with a known history of chronic viral infections as indicated below
- Participants with a history of allogeneic tissue/solid organ transplant
- Participants must not have any serious or uncontrolled medical disorder that, in the opinion of the investigator, may increase the risk associated with study participation or study treatment administration, impair the ability of the participant to receive protocol therapy, or interfere with the interpretation of study results
- Patients with a TnT or troponin I (TnI) > 2x institutional ULN at baseline. Patients with Troponin T (TnT) or troponin levels between > 1 to 2x ULN are permitted if repeat levels within 24 hours are ≤ 1x ULN. If TnT or TnI levels are > 1 to 2x ULN within 24 hours, the subject may undergo a cardiac evaluation and be considered for treatment by the investigator based on the medical judgement in the patient's best interest
- HIV infection with CD4 count <200/microliter as measured within screening time period. Patients with HIV infectious should be on combination antiretroviral medication
- Participants with visceral, bone, or brain metastases
- Participants with a diagnosis of acral, ocular or mucosal melanoma
- Participants with known untreated or symptomatic central nervous system (CNS) metastases and/or carcinomatous meningitis
- Positive pregnancy test during screening. Pregnant or lactating women are prohibited from enrolling in this study
Where in United States
- Chao Family Comprehensive Cancer Center, University of California, IrvineOrange, United StatesContact: Chao Family Comprehensive Cancer Center University of California, IrvineNot yet recruiting
About the trial
What the trial wants to find out
This is a phase II, open label clinical trial determining efficacy of Fianlimab in combination with Cemiplimab in subjects with Melanoma. These are subjects who will have surgery to remove their cancer.
The 3 groups in the trial
- 3 doses of neoadjuvant of Fianlimab in combination with CemiplimabTreatment being tested
3 doses of neoadjuvant 1600 mg Fianlimab in combination with 350 mg Cemiplimab every 3 weeks, followed by Surgery and then 13 doses of 1600 mg Fianlimab in combination with 350 mg Cemiplimab every 3 weeks
Treatment: Fianlimab and Cemiplimab
- 6 doses of neoadjuvant Fianlimab in combination with CemiplimabTreatment being tested
6 doses of neoadjuvant 1600 mg Fianlimab in combination with 350 mg Cemiplimab every 3 weeks, followed by Surgery and then 10 doses of 1600 mg Fianlimab in combination with 350 mg Cemiplimab every 3 weeks
Treatment: Fianlimab and Cemiplimab
- 8 doses of neoadjuvant Fianlimab in combination with CemiplimabTreatment being tested
8 doses of neoadjuvant 1600 mg Fianlimab in combination with 350 mg Cemiplimab every 3 weeks, followed by Surgery and then 8 doses of 1600 mg Fianlimab in combination with 350 mg Cemiplimab every 3 weeks
Treatment: Fianlimab and Cemiplimab
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorSaves a reminder to your own calendar to look at this page again. Frontlight sends no messages and does not know you set it.
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Fianlimab and Cemiplimab as Total Neoadjuvant Therapy (TNT) For Melanoma
- Plain-language title
- Testing fianlimab with cemiplimab before surgery for melanomaGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 12 November 2026.
- Record updated
- 11 September 2026